Xeno Transplants Corp. operates as a bio-technology research and development company. The company, through a license agreement with Massachusetts General Hospital, intends to develop, manufacture, distribute, and use products and processes for public use with regard to xenotransplantation. Xenotransplantation is intended to address the problems arising from the limited supply of available human cells, tissues, and organs for transplantation by developing technologies to permit the transplantation of cells, tissues, and organs from other species, such as swine, into humans. Transplant Programs The company is also evaluating other GalT-KO xenotransplant product development opportunities for major unmet medical needs. Islet Cell Transplantation The company is exploring technology options and collaborations for developing the use of porcine pancreatic islet cells from its GalT-KO miniature swine to treat brittle type 1 diabetics and diabetic patients with renal failure. Competition The company identifies competition from Revivicor and the Mayo Clinic group. History Xeno Transplants Corp. was founded in 2006.
xeno transplants corp (XENO:OTC US)
143 Gardner Road
Brookline, MA 02445
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for XENO.|
|View Industry Companies|
|Price/Cash Flow||--||Not Meaningful|
Sponsored Financial Commentaries
To contact XENO TRANSPLANTS CORP, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.